Rigel: Tavalisse NDA Will Be A Game-Changer

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) is banking everything on fostamitinib, its oral spleen tyrosine kinase inhibitor for the treatment of patients with chronic and persistent Idiopathic Thrombocytopenic Parpura (ITP). So much so, in fact, that the company has gone ahead and registered a trade name for the drug candidate with the USPTO. This trade name, Tavalisse, has also been provisionally accepted by the US Food and Drug Administration.

Back to news